Zuclopenthixol acetate

Zuclopenthixol acetate is used to manage the acute symptoms of serious mental illnesses like schizophrenia, particularly for agitated or violent patients. It is a short-acting injectable that provides initial sedation and has an antipsychotic effect to help calm aggressive behavior and manage delusions and hallucinations. This formulation is for acute management, with its effects lasting up to 72 hours, and is typically a last-line option when rapid tranquilization is required. The directory classifies it as a commercial API with a semi-synthetic source/manufacturing origin. Other names for this substance include Clopenthixol acetate ester and Clopixol Acuphase. Its PubChem CID is 6436640.